AlloVir (ALVR) said Friday it signed a definitive agreement to merge with Kalaris Therapeutics (KLRS) in an all-stock transaction.
The combined company will take on the name of Kalaris Therapeutics and is expected to trade on Nasdaq under the ticker symbol "KLRS," AlloVir said.
It will have around $100 million in cash upon closing, AlloVir said, adding that the cash is expected to fund the combined company's operations through Q4 of 2026.
AlloVir will acquire all of Kalaris' outstanding equity interest and said its shareholders will own around 25% of the combined company when the transaction closes, while shareholders of pre-merger Kalaris will own roughly 75%.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。